18:50 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Innovation's Brilacidin-OM meets in Phase II for oral mucocitis

Innovation Pharmaceuticals Inc. (OTCQB:IPIX) reported top-line data from 46 patients receiving chemoradiation for head and neck cancer in the modified intent-to-treat (mITT) population of a Phase II trial showing that thrice-daily 45 mg/15 mL Brilacidin-OM...
19:19 , May 24, 2017 |  BC Week In Review  |  Clinical News

Cellceutix completes enrollment in Phase II for ulcerative proctitis

Cellceutix Corp. (OTCQB:CTIX) completed enrollment of 17 patients with mild to moderate ulcerative proctitis or proctosigmoiditis in a Phase II trial evaluating once-daily 50, 100 and 200 mg brilacidin via retention enema for 6 weeks....
20:22 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

Kevetrin: Ph IIa started

Cellceutix began an open-label, U.S. Phase IIa trial to evaluate 250 and 350 mg/m 2 IV Kevetrin thrice weekly for 3 weeks in about 10 patients. Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass.  Product: Kevetrin thioureidobutyronitrile  Business:...
23:05 , Nov 2, 2016 |  BC Week In Review  |  Clinical News

Prurisol: Ph IIb started

Cellceutix began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 150 and 200 mg oral Prurisol twice daily for 12 weeks in about 189 patients. The company is developing Prurisol under section 505(b)(2) of...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Kevetrin thioureidobutyronitrile: Additional Phase I data

An open-label, dose-escalation, U.S. Phase I trial in about 48 patients with advanced solid tumors showed that once-weekly 10-750 mg/m 2 IV Kevetrin given for the first 3 weeks of each 4-week cycle met the...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

Brilacidin: Phase II started

Cellceutix began an observer-blind Phase II trial to evaluate 3 dose levels of once-daily brilacidin given via retention enema for 6 weeks in 18 patients. Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass.   Product: Brilacidin   Business:...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Prurisol abacavir acetate: Phase II ongoing

Cellceutix completed dosing in a double-blind, placebo-controlled, U.S. Phase II trial evaluating oral Prurisol for 84 days in 115 patients with mild to moderate chronic plaque psoriasis. Prurisol was dosed at 50 mg once daily,...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Kevetrin thioureidobutyronitrile: Completed Phase I enrollment

Cellceutix completed enrollment of >40 patients in an open-label, dose-escalation, U.S. Phase I trial evaluating IV Kevetrin given once weekly for the first 3 weeks of a 4-week cycle. Next half, the company plans to...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

Thioureidobutyronitrile: Interim Phase I data

Interim data from 1 patient with stage IV thymoma in his eleventh month of treatment in an open-label, dose-escalation, U.S. Phase I trial showed that once-weekly IV Kevetrin for the first 3 weeks of a...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Abacavir acetate: Phase II started

Cellceutix began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 50, 100 and 200 mg daily Prurisol in about 100 patients. The company is developing Prurisol under section 505(b)(2) of the Food, Drug and...